Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million to support its growth and clinical strategy [1][4]. Group 1: Offering Details - The public offering consists of 34,782,609 shares priced at $5.75 each, with expected gross proceeds of around $200 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 5,217,391 shares at the public offering price [2]. - The offering is set to close on January 22, 2026, pending customary closing conditions [1]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, with a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the offering [3]. - The completion of the private placement is contingent on the successful completion of the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the offering and private placement will be used to advance the clinical strategy, including the DurAVR® THV global pivotal trial for severe aortic stenosis [4]. - Additional funds will support the expansion of manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining funds allocated to working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is a global structural heart company focused on developing innovative medical devices to restore heart function [10]. - The lead product, DurAVR® THV, is designed to treat aortic stenosis and is made from Anteris' patented ADAPT® tissue technology, which has been used in over 55,000 patients worldwide [11].